Pharma BD Deal Intelligence

Merck & Co. Inc. / Infinimmune, Inc.

2026 · Licensing/Option · $838M · Complete

Infinimmune entered a research collaboration and license agreement with Merck & Co. to apply its human-first Anthrobody discovery platform and GLIMPSE antibody language model to identify and optimize antibody candidates against multiple undisclosed Merck-designated targets. Merck holds the exclusive right to develop and commercialize resulting candidates. Infinimmune receives an undisclosed upfront payment and is eligible for milestones totaling up to approximately $838M across multiple antibody candidates.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Merck & Co. Inc. deals